Table 3.
Association Between YKL-40 (per SD Unit Increase) and Conversion From MCI to Dementia in the ACE Cohort
| Model adjustments | CSF YKL-40 | Plasma YKL-40 | ||||
| Events/N | HR (95% CI) | p Value | Events/N | HR | p Value | |
| Age, sex | 213/435 | 1.34 (1.15–1.57) | <0.001 | 326/751 | 1.12 (0.004–0.23) | 0.04 |
| Age, sex, ATN classificationa | 213/435 | 1.24 (1.04–1.48) | 0.02 | 326/751 | 1.16 (0.04–0.26) | 0.01 |
Abbreviations: ATN = amyloid, tau, and neurodegeneration biomarker classification; MCI = mild cognitive impairment.
Participants were followed up from the time of the LP/blood draw for a median (Q1, Q3, max) of 2.1 (1.1, 3.3, 6.4) years. CSF YKL-40 was measured with an Olink assay and plasma YKL40 was measured with a SOMAscan assay.
a
ATN categories based on: doi.org/10.3390/ijms23136891.